Targeting MCL-1 to Overcome Therapeutic Resistance and Improve Cancer Mortality

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Myeloid cell leukemia-1 protein (MCL-1) is a key anti-apoptotic protein overexpressed in various malignancies, including lung cancer and leukemia.
• MCL-1 overexpression supports tumor cell survival, drives therapeutic resistance, and leads to poor patient outcomes by inhibiting apoptosis.
• Targeting MCL-1 with small-molecule inhibitors has emerged as a promising therapeutic strategy.

Purpose of the Study:

• To review the dual roles of MCL-1 in apoptosis and mitochondrial homeostasis.
• To summarize the structural basis and pharmacological profiles of leading MCL-1 inhibitors.
• To discuss emerging strategies for MCL-1 inhibition, including combination therapies and novel drug designs.

Main Methods:

• Literature review of current knowledge on MCL-1.
• Summary of structural aspects for MCL-1 inhibitor design.
• Analysis of clinical development of MCL-1 inhibitors (S63845, AZD5991, AMG 176).

Main Results:

• MCL-1 plays critical roles in both apoptosis regulation and mitochondrial homeostasis.
• Leading MCL-1 inhibitors are in advanced clinical development, with ongoing research into combination therapies and PROTAC strategies.
• Overexpression of MCL-1 is linked to worse patient survival in specific cancer types (ACC, CESC, ESCA, HNSC, LGG, UVM).

Conclusions:

• MCL-1 is a significant anti-cancer target with the potential to sensitize resistant tumors and improve survival.
• Clinical success hinges on optimized dosing, rational combination therapies, and adaptive trial designs.
• Continued translational research is essential to fully harness the therapeutic potential of MCL-1 inhibition.